AbbVie Inc. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 8/100
What the filing says
AbbVie recorded $216 million in acquired in-process R&D (IPR&D) and milestone expenses in Q3 2026, reducing full-year 2026 adjusted diluted EPS guidance from $13.87–$14.07 to $13.76–$13.96 (a $0.11 reduction at midpoint). The company excluded potential future IPR&D and milestone expenses beyond Q3 2026 from guidance due to forecasting uncertainty. No counterparties, deal details, or additional context are disclosed in this filing excerpt.
Why this rating
Q3 IPR&D charge of $216M is ~0.07% of $325B market cap—routine. EPS reduction modest (~0.8%). Implies active R&D acquisition activity but immaterial to company scale.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.